Highlights on atezolizumab combined with FOLFOXIRI + bevacizumab in 1st-line metastatic colorectal cancer: AtezoTRIBE study
ESMO 2021: AtezoTRIBE study
Share.
Highlights on atezolizumab combined with FOLFOXIRI + bevacizumab in 1st-line metastatic colorectal cancer: AtezoTRIBE study
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.